Monoclonal antibody development

Please fill out this form as a prerequisite for planning and specifying the major steps of the respective project.

It will also be used as the basic for quotation and further discussion of project details.

All information provided will be treated strictly confidential. A secrecy agreement can be signed.

CLIENT

Company/Institution name: _____

Contact person: _____

Address: _____

_____

_____

_____

_____

Phone: _____

Fax: _____

Email: _____

Date: _____

BioGenes GmbH
Koepenicker Str. 325, 12555 Berlin, Germany
Fax +49 (0) 30 6576 2397
Email: katrin.krusemark@biogenes.de

1. ANTIGEN – ANTIBODY

Name:

Isotype, and Subclass (if known):

Antibody is available as:

☐ **Whole molecule** ☐ **F(ab')$_2$-Fragment**

☐ **Fab-Fragment** ☐ **scFv/Fv-Fragment**

Fragmentation wanted?

☐ **yes** ☐ **no**

Antibody host species, respecively Fc/Fv part from what species:

☐ **Human** ☐ **Rat**

☐ **Mouse** ☐ **Other**

Modified Antibody:

☐ **humanised** ☐ **chimeric**

Antibody-conjugate:

Structure of the conjugate (hapten), including the linker, respectively annotate the group that is used for conjuagtion to the antibody:

Characterisation and structure of the drug substance:

BioGenes GmbH
Koepenicker Str. 325, 12555 Berlin, Germany
Fax +49 (0) 30 6576 2397
Email: katrin.krusemark@biogenes.de

Is the drug substance a cell toxintoxic? If yes, in what respect, e.g. cell toxin or else, please describe

Antibody or Antibody-conjugate is available in buffer:

☐ soluble ☐ precipitated

Concentration:

Volume:

Buffer content:

Antibody or Antibody-conjugate is lyophilised:

Amount:

Lyophilised from which buffer?

Lyophilised from which volume?

To be reconstituted in which buffer?

Preservative ☐ If yes, which?

Storage conditions: ☐ 4° C ☐ -20° C ☐ -80° C

If information about **stability** during longterm storage is available, please specify:

Identification of an anti-idiotypic antibody recognising the antibody binding site wanted? ☐

If yes, original antigen available? ☐

is the original antigen available? Yes ☐ **No** ☐

Amount of antigen**:**

BioGenes GmbH
Koepenicker Str. 325, 12555 Berlin, Germany
Fax +49 (0) 30 6576 2397
Email: katrin.krusemark@biogenes.de

Available in buffer:

☐ soluble ☐ precipitated

Concentration:

Volume:

Buffer content::

Antigen is lyophilised:

Amount:

Lyophilised from which buffer?

Lyophilised from which volume?

To be reconstituted in which buffer?

Preservative ☐ If yes, which ?

Storage conditions: ☐ 4° C ☐ -20° C ☐ -80° C

Are monoclonal or polyclonal antibodies against the above mentioned antibody antigen (in this case antibody) commercially available?

Specifications, publications and/or details regarding to the development of commercially available monoclonal or polyclonal antibodies against the above mentioned antibodyantigen (in this case antibody):

BioGenes GmbH
Koepenicker Str. 325, 12555 Berlin, Germany
Fax +49 (0) 30 6576 2397
Email: katrin.krusemark@biogenes.de

2. ANTIBODY (DEVELOPMENT)

Development in: ☐ Mouse

Should cross reactivities be included or excluded? ☐ yes ☐ no

Kind of selection: ☐ positive selection ☐ negative selection

☐ cross-reactivity test for characterisation only

Are cross reactants available? ☐ yes ☐ no

Are cross reactants commercially available? Source?

Information about cross reactant:

Name:

Purity:

Molecular weight:

Available in buffer:

☐ soluble ☐ precipitated

Concentration:

Volume:

Buffer content:

Cross reactant is lyophilised:

Amount:

Lyophilised from which buffer?

BioGenes GmbH
Koepenicker Str. 325, 12555 Berlin, Germany
Fax +49 (0) 30 6576 2397
Email: katrin.krusemark@biogenes.de

Lyophilised from which volume?

To be reconstituted in which buffer?

Preservative ☐ If yes, which ?

Storage conditions : ☐ 4° C ☐ -20° C ☐ -80° C

If information about **stability** during longterm storage available, please specify:

3. ANTIBODIES TO BE USED IN

Westernblot	☐ yes	☐ no
ELISA	☐ yes	☐ no
Immunhistochemistry	☐ yes	☐ no
Immunofluorescence assay (IFA)	☐ yes	☐ no
Immunoassay development	☐ yes	☐ no

Other:

Preparation of cell culture supernatant for testing:

Preservative:

☐ NaN_3 ☐ Thimerosal ☐ ProClin ☐ no preservative

☐ 0.2µm filtrated ☐ not filtrated

4. FUTURE PLANS WITH MABS AT BIOGENES

Modification:	☐ yes	☐ no
If yes, which kind?		
Production:	☐ yes	☐ no
Pair search (capture/detector):	☐ yes	☐ no

BioGenes GmbH
Koepenicker Str. 325, 12555 Berlin, Germany
Fax +49 (0) 30 6576 2397
Email: katrin.krusemark@biogenes.de

Immunoassay development: ☐ yes ☐ no

If yes, which kind?

Storage of cryo cultures at BioGenes:

☐ yes ☐ no

If yes, ☐ with taking care ☐ without taking care

5. ADDITIONAL INFORMATION

BioGenes GmbH
Koepenicker Str. 325, 12555 Berlin, Germany
Fax +49 (0) 30 6576 2397
Email: katrin.krusemark@biogenes.de